Cardiac AL Amyloidosis: PET/CT Imaging Study

We are studying a new non-invasive imaging method to diagnose cardiac AL amyloidosis in patients with a specific type of protein in their blood. This research aims to see if this method is as effective as traditional invasive tests.

1-2 years≤5 visitsConfirmation phase (III)No PlaceboStandard MedicinesInjectionCardiologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Neuraceq
Neuraceq is a PET imaging agent used to help detect brain changes linked to Alzheimer’s disease.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Florbetaben (18f)
Florbetaben (18F) is a radioactive imaging tracer used in PET scans to show amyloid plaque buildup in the brain for Alzheimer's evaluation.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
University Hospital Of Ferrara
Divisione Cardiologia
Ferrara, Italy
Fondazione IRCCS Policlinico San Matteo
Dip. Medicina Diagnostica e dei Servizi
Pavia, Italy
Fondazione Toscana Gabriele Monasterio
U.O.C. Cardiologia e Medicina Cardiovascolare
Pisa, Italy
Sponsor: Fondazione Toscana Gabriele Monasterio
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.